BIOMAT Database Logo BIOMAT Database Logo

Carboplatin in malignant mesothelioma: a phase II study of the Cancer and Leukemia Group B. 1990

N J Vogelzang, and M Goutsou, and J M Corson, and Y Suzuki, and S Graziano, and J Aisner, and M R Cooper, and K M Coughlin, and M R Green
University of Chicago, Joint Section of Hematology/Oncology, Illinois 60637.

Carboplatin (400 mg/m2) was given at 28-day intervals to 41 patients with malignant mesothelioma. In all, 40 patients were eligible and evaluable for response. Partial responses were seen in 2 cases (5%); regression of evaluable disease, in 1 patient (2%); and stable disease, in 19 subjects (48%). A median of two doses of carboplatin per patient resulted in mild toxicity. Leukopenia (less than or equal to 2,000 cells/microliters) and thrombocytopenia (less than 100,000 cells/microliters) were seen in only 6% and 20% of the patients, respectively. Median survival from study entry was estimated at 7.1 months, with a 1-year survival of 25% +/- 7%. Carboplatin given at a dose of 400 mg/m2 at 28-day intervals shows minor activity against malignant mesothelioma.

UI MeSH Term Description Entries
D008297 Male Males
D008654 Mesothelioma A tumor derived from mesothelial tissue (peritoneum, pleura, pericardium). It appears as broad sheets of cells, with some regions containing spindle-shaped, sarcoma-like cells and other regions showing adenomatous patterns. Pleural mesotheliomas have been linked to exposure to asbestos. (Dorland, 27th ed) Mesotheliomas
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D004341 Drug Evaluation Any process by which toxicity, metabolism, absorption, elimination, preferred route of administration, safe dosage range, etc., for a drug or group of drugs is determined through clinical assessment in humans or veterinary animals. Evaluation Studies, Drug,Drug Evaluation Studies,Drug Evaluation Study,Drug Evaluations,Evaluation Study, Drug,Evaluation, Drug,Evaluations, Drug,Studies, Drug Evaluation,Study, Drug Evaluation
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D000368 Aged A person 65 years of age or older. For a person older than 79 years, AGED, 80 AND OVER is available. Elderly
D015996 Survival Rate The proportion of survivors in a group, e.g., of patients, studied and followed over a period, or the proportion of persons in a specified group alive at the beginning of a time interval who survive to the end of the interval. It is often studied using life table methods. Cumulative Survival Rate,Mean Survival Time,Cumulative Survival Rates,Mean Survival Times,Rate, Cumulative Survival,Rate, Survival,Rates, Cumulative Survival,Rates, Survival,Survival Rate, Cumulative,Survival Rates,Survival Rates, Cumulative,Survival Time, Mean,Survival Times, Mean,Time, Mean Survival,Times, Mean Survival
D016190 Carboplatin An organoplatinum compound that possesses antineoplastic activity. cis-Diammine(cyclobutanedicarboxylato)platinum II,Blastocarb,CBDCA,Carboplat,Carbosin,Carbotec,Ercar,JM-8,NSC-241240,Nealorin,Neocarbo,Paraplatin,Paraplatine,Platinwas,Ribocarbo,JM 8,JM8,NSC 241240,NSC241240

Related Publications

N J Vogelzang, and M Goutsou, and J M Corson, and Y Suzuki, and S Graziano, and J Aisner, and M R Cooper, and K M Coughlin, and M R Green
Trimetrexate in malignant mesothelioma: A Cancer and Leukemia Group B Phase II study.
July 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology,
N J Vogelzang, and M Goutsou, and J M Corson, and Y Suzuki, and S Graziano, and J Aisner, and M R Cooper, and K M Coughlin, and M R Green
Gefitinib in patients with malignant mesothelioma: a phase II study by the Cancer and Leukemia Group B.
March 2005, Clinical cancer research : an official journal of the American Association for Cancer Research,
N J Vogelzang, and M Goutsou, and J M Corson, and Y Suzuki, and S Graziano, and J Aisner, and M R Cooper, and K M Coughlin, and M R Green
A phase II study of sorafenib in malignant mesothelioma: results of Cancer and Leukemia Group B 30307.
October 2010, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer,
N J Vogelzang, and M Goutsou, and J M Corson, and Y Suzuki, and S Graziano, and J Aisner, and M R Cooper, and K M Coughlin, and M R Green
Irinotecan for malignant mesothelioma A phase II trial by the Cancer and Leukemia Group B.
June 2005, Lung cancer (Amsterdam, Netherlands),
N J Vogelzang, and M Goutsou, and J M Corson, and Y Suzuki, and S Graziano, and J Aisner, and M R Cooper, and K M Coughlin, and M R Green
Gemcitabine for malignant mesothelioma: A phase II trial by the Cancer and Leukemia Group B.
January 2001, Lung cancer (Amsterdam, Netherlands),
N J Vogelzang, and M Goutsou, and J M Corson, and Y Suzuki, and S Graziano, and J Aisner, and M R Cooper, and K M Coughlin, and M R Green
Capecitabine in malignant mesothelioma: a phase II trial by the Cancer and Leukemia Group B (39807).
May 2004, Lung cancer (Amsterdam, Netherlands),
N J Vogelzang, and M Goutsou, and J M Corson, and Y Suzuki, and S Graziano, and J Aisner, and M R Cooper, and K M Coughlin, and M R Green
Vatalanib in malignant mesothelioma: a phase II trial by the Cancer and Leukemia Group B (CALGB 30107).
June 2012, Lung cancer (Amsterdam, Netherlands),
N J Vogelzang, and M Goutsou, and J M Corson, and Y Suzuki, and S Graziano, and J Aisner, and M R Cooper, and K M Coughlin, and M R Green
Phase II trial of carboplatin in advanced breast carcinoma: a Cancer and Leukemia Group B Study.
January 1985, Cancer treatment reports,
N J Vogelzang, and M Goutsou, and J M Corson, and Y Suzuki, and S Graziano, and J Aisner, and M R Cooper, and K M Coughlin, and M R Green
High-dose doxorubicin, dexrazoxane, and GM-CSF in malignant mesothelioma: a phase II study-Cancer and Leukemia Group B 9631.
November 2001, Lung cancer (Amsterdam, Netherlands),
N J Vogelzang, and M Goutsou, and J M Corson, and Y Suzuki, and S Graziano, and J Aisner, and M R Cooper, and K M Coughlin, and M R Green
Dihydro-5-azacytidine and cisplatin in the treatment of malignant mesothelioma: a phase II study by the Cancer and Leukemia Group B.
April 1998, Cancer,
Copied contents to your clipboard!